- HK$19.12bn
- HK$9.32bn
- $630.20m
- 22
- 40
- 34
- 18
RCS - Hutchmed China Ltd - Enrollment Complete in SAFFRON Global Phase III
AnnouncementRCS - Hutchmed China Ltd - Updates from R&D Event
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Presents Data at AACR NCI EORTC
AnnouncementREG - Hutchmed China Ltd - Vesting of awards under Long Term Incentive Plan
AnnouncementREG - Hutchmed China Ltd - Appointment of Independent Non-executive Director
AnnouncementRCS - Hutchmed China Ltd - Data to be Presented at the 2025 ESMO Congress
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Highlights Data to be Presented at ESMO
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED to Present R&D Updates on October 31 2025
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Highlights Data to be Presented at CSCO
AnnouncementREG - Hutchmed China Ltd - Directorate Change
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED Completes Enrollment of Phase III Trial
AnnouncementREG - Hutchmed China Ltd - 2025 Interim Results
AnnouncementREG - Hutchmed China Ltd - HUTCHMED to Announce 2025 Half-Year Results
AnnouncementREG - Hutchmed China Ltd - Update on Joint Corporate Brokers in London
AnnouncementREG - Hutchmed China Ltd - Total Voting Rights
AnnouncementREG - Hutchmed China Ltd - China Approval based on Phase III SACHI Trial
AnnouncementREG - Hutchmed China Ltd - Blocklisting Six Monthly Return
AnnouncementREG - Hutchmed China Ltd - Grant of Share Options and Awards under LTIP
Announcement